Children AKI Patients Clinical Trial
Official title:
A 52-week Multicenter, Randomized, Double-blind, Prospective Study to Evaluate Comparative Effectiveness and Safety of Alprostadil Injection,Sodium Ferulate and Dopamine Injection in Pediatric Acute Kidney Injury
Acute kidney injury (AKI) is a pervasive clinical event in children.It has been independently
associated with prolonged hospital stays, risk of in-hospital death and future progression to
chronic kidney disease. Except for removal of nephrotoxic agents and optimization of
supportive care,there are still no other effective therapeutic options recommended by recent
guidelines. Renal ischemia is the main mechanism of AKI, the improving microcirculation
therapy would be the effective management to improve the outcome of AKI in children.
Dopamine is a vasodilating drug that in small doses improves renal circulation. Alprostadil
have been used in chronic arterial occlusion and Sodium Ferulate in ischemic cerebral
vascular disease,they have a similar therapeutic effect of anti-platelet aggregation and
vasodilation. Recent research shows that alprostadil might be associated with a significant
reduction in postcontrast Scr, blood urine nitrogen (BUN) and Cystatin C (CysC) level and
decrease the incidence of contrast-induced nephropathy.The investigators speculate that
Alprostadil,Sodium Ferulate and dopamine would be effective in treating AKI in children.
This is a prospective, multicenter, randomized, double-blind, 52-week study. The purpose of
this study is to evaluate the comparative effectiveness and safety of Alprostadil,Sodium
Ferulate and dopamine in improving the outcome of AKI in children.
This study aims to explore the effective treatment of pediatric AKI and improve the outcome. It is a 52-week multicenter, randomized, double-blind,prospective study to evaluate comparative effectiveness and safety of alprostadil injection,sodium ferulate and dopamine injection. This study plans to recruit 8 to 10 centers, with 300 participants randomly divided into 3 groups and given respectively Alprostadil 0.2~0.3ug/kg.h,iv,1h/d,14d,Sodium Ferulate2~6mg/kg.d,iv,14d,Dopamine3~5ug/kg .min,iv,3h/d,14d.Time of outcome measurement is 1w,2w,4w,24w,52w. Primary Outcome Measures is The change of Serum creatinin from baseline, estimated glomerular filtration rate (eGFR) and urine volume in the participants after the use of the study drug. ;